Vaccinia virus serpin B13R (SPI-2) inhibits interleukin-1beta-converting enzyme and protects virus-infected cells from TNF- and Fas-mediated apoptosis, but does not prevent IL-1beta-induced fever - PubMed (original) (raw)
Vaccinia virus serpin B13R (SPI-2) inhibits interleukin-1beta-converting enzyme and protects virus-infected cells from TNF- and Fas-mediated apoptosis, but does not prevent IL-1beta-induced fever
S Kettle et al. J Gen Virol. 1997 Mar.
Abstract
The vaccinia virus (VV) strain Western Reserve B13R gene encodes a 38.5 kDa intracellular polypeptide that is non-essential for virus replication in vitro and does not affect virus virulence in a murine intranasal model. The protein has 92% amino acid identity with the cowpox virus cytokine response modifier A (crmA) protein which inhibits the interleukin (IL)-1beta converting enzyme (ICE). Here, we show that extracts from THP-1 cells infected with VV strains expressing B13R prevent the cleavage of in vitro transcribed and translated pro-IL-1beta into mature IL-1beta. Similarly, THP-1 cells infected with VVs expressing B13R process pro-IL-1beta into mature IL-1beta inefficiently in situ. Despite its inhibition of ICE, B13R does not prevent fever in infected mice, a systemic effect mediated by IL-1beta. Instead, fever is controlled by the VV IL-1beta receptor, encoded by gene B15R, and deletion of both the B13R and B15R genes did not increase the febrile response compared to deletion of B15R alone. The B13R protein does, however, block apoptosis mediated by anti-Fas antibodies or by tumour necrosis factor (TNF) and cycloheximide. Using DNA fragmentation, chromium release and microscopic analyses it was shown that cells infected with wild-type VV strain WR, or a revertant virus in which the B13R gene had been re-inserted into the B13R deletion mutant, are more resistant than uninfected cells or deletion mutant-infected cells to apoptosis mediated by anti-Fas and TNF.
Similar articles
- Vaccinia virus serpins B13R and B22R do not inhibit antigen presentation to class I-restricted cytotoxic T lymphocytes.
Blake NW, Kettle S, Law KM, Gould K, Bastin J, Townsend AR, Smith GL. Blake NW, et al. J Gen Virol. 1995 Sep;76 ( Pt 9):2393-8. doi: 10.1099/0022-1317-76-9-2393. J Gen Virol. 1995. PMID: 7561783 - Induction of potent humoral and cell-mediated immune responses by attenuated vaccinia virus vectors with deleted serpin genes.
Legrand FA, Verardi PH, Jones LA, Chan KS, Peng Y, Yilma TD. Legrand FA, et al. J Virol. 2004 Mar;78(6):2770-9. doi: 10.1128/jvi.78.6.2770-2779.2004. J Virol. 2004. PMID: 14990697 Free PMC article. - Activation of caspases in pig kidney cells infected with wild-type and CrmA/SPI-2 mutants of cowpox and rabbitpox viruses.
Macen J, Takahashi A, Moon KB, Nathaniel R, Turner PC, Moyer RW. Macen J, et al. J Virol. 1998 May;72(5):3524-33. doi: 10.1128/JVI.72.5.3524-3533.1998. J Virol. 1998. PMID: 9557631 Free PMC article. - Protection against apoptosis by the vaccinia virus SPI-2 (B13R) gene product.
Dobbelstein M, Shenk T. Dobbelstein M, et al. J Virol. 1996 Sep;70(9):6479-85. doi: 10.1128/JVI.70.9.6479-6485.1996. J Virol. 1996. PMID: 8709286 Free PMC article.
Cited by
- Analysis of the monkeypox virus genome.
Shchelkunov SN, Totmenin AV, Safronov PF, Mikheev MV, Gutorov VV, Ryazankina OI, Petrov NA, Babkin IV, Uvarova EA, Sandakhchiev LS, Sisler JR, Esposito JJ, Damon IK, Jahrling PB, Moss B. Shchelkunov SN, et al. Virology. 2002 Jun 5;297(2):172-94. doi: 10.1006/viro.2002.1446. Virology. 2002. PMID: 12083817 Free PMC article. - Resistance to vaccinia virus is less dependent on TNF under conditions of heterologous immunity.
Nie S, Cornberg M, Selin LK. Nie S, et al. J Immunol. 2009 Nov 15;183(10):6554-60. doi: 10.4049/jimmunol.0902156. Epub 2009 Oct 21. J Immunol. 2009. PMID: 19846867 Free PMC article. - Poxvirus homologues of cellular genes.
Bugert JJ, Darai G. Bugert JJ, et al. Virus Genes. 2000;21(1-2):111-33. Virus Genes. 2000. PMID: 11022794 Review. - Vaccinia virus infection disarms the mitochondrion-mediated pathway of the apoptotic cascade by modulating the permeability transition pore.
Wasilenko ST, Meyers AF, Vander Helm K, Barry M. Wasilenko ST, et al. J Virol. 2001 Dec;75(23):11437-48. doi: 10.1128/JVI.75.23.11437-11448.2001. J Virol. 2001. PMID: 11689625 Free PMC article. - Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics.
Guo ZS, Lu B, Guo Z, Giehl E, Feist M, Dai E, Liu W, Storkus WJ, He Y, Liu Z, Bartlett DL. Guo ZS, et al. J Immunother Cancer. 2019 Jan 9;7(1):6. doi: 10.1186/s40425-018-0495-7. J Immunother Cancer. 2019. PMID: 30626434 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous